SimBioSys announced today that it entered into a strategic collaboration with Mayo Clinic to develop digital precision medicine solutions.
The collaboration aims to develop cloud-based clinical software to support end-to-end decision-making for early-stage breast cancer patients. This includes individualized surgical planning, treatment, drug selection and risk stratification.
As part of the collaboration, SimBioSys has had access to and has analyzed data from patients participating in the Mayo Clinic-led BEAUTY clinical trial. The company uses AI and data science to unlock spatial biophysical insights to help clinicians tailor treatment plans for each patient.
SimBioSys plans to perform simulations using previously acquired data. While validating the platform’s predictive accuracy, it also expects to perform in-silico scenario analysis guided by the Mayo team.
The company offers its TumorSight cloud-based platform for use during the treatment planning process. Its first product on the platform — currently under FDA review — takes a patient’s standard-of-care imaging to build a custom 3D model of their tumor. The tool provides 3D spatial visualizations of breast cancer to support more effective planning and consultations.
“In the crowded world of genomics, new approaches have many barriers to becoming a new standard of care,” said Tushar Pandey, co-founder and CEO of SimBioSys. “SimBioSys complements current precision medicine techniques while only relying on readily available and previously acquired datasets such as imaging. We are delighted to collaborate with Mayo Clinic as we bring our innovative technology to patients.”